Small caps round-up: James Cropper, ValiRx, ReNeuron
James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current year and is expected to result in cost savings of around one million pounds each year. The firm added that it will be necessary to make a provision of 0.8m pounds in the financial statement for redundancy payments.
James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current year and is expected to result in cost savings of around one million pounds each year. The firm added that it will be necessary to make a provision of 0.8m pounds in the financial statement for redundancy payments.
ValiRx, the AIM-listed life sciences firm, has boasted a 157% rise in revenue for 2011, up from £0.177m to £0.455m following a 'signficant' capital injection. During the period the company was in receipt of $1.1m, the procees of the sale of its subsidiary diagnostic development business.
Despite this and a halving of sales costs, the company made a pre-tax loss of £1.1m (2010: £0.1m). The was partly the result of a doubling of admin expenses and a rise in research and development costs. A number of the company's therapeutic products are on the cusp of entering clinical trials, the firm said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
ReNeuron Group, the Surrey-based stem cell developer, has raised £5.4m through the placing of over 134m shares at 4p per share. In addition the company gave all qualifying shareholders with the opportunity to subscribe, also at 4p per share, for an aggregate of up to 99,744,494 open offer shares, for which the company received acceptance for just under 17.4m. This generated £0.7m.
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?
Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
By Kalpana Fitzpatrick Published
-
What does Rachel Reeves’s plan for growth mean for UK investors?
Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
By Katie Williams Published